BioAtla (NASDAQ:BCAB) Downgraded by HC Wainwright to Neutral

HC Wainwright cut shares of BioAtla (NASDAQ:BCAB) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, MarketBeat.com reports.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of BioAtla in a research report on Monday, September 16th.

BioAtla Stock Down 9.1 %

BioAtla stock opened at $1.99 on Wednesday. The company has a market capitalization of $96.20 million, a PE ratio of -1.17 and a beta of 1.03. The firm has a fifty day simple moving average of $1.92 and a two-hundred day simple moving average of $1.88. BioAtla has a twelve month low of $1.14 and a twelve month high of $4.02.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same quarter in the previous year, the business posted ($0.70) EPS. As a group, equities analysts expect that BioAtla will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAtla

Several hedge funds have recently bought and sold shares of BCAB. Massachusetts Financial Services Co. MA lifted its stake in shares of BioAtla by 5.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after purchasing an additional 28,133 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in BioAtla during the third quarter worth about $623,000. Chicago Partners Investment Group LLC purchased a new position in BioAtla during the third quarter worth approximately $44,000. Vontobel Holding Ltd. purchased a new position in BioAtla during the third quarter worth approximately $28,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of BioAtla in the second quarter valued at approximately $99,000. Institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.